Physician profile
Jonathan Grossman
NPI 1093210114
$2,204.74
in general payments reported to CMS, 2019-2025
33 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.65 · 2020: $80.51 · 2021: $59.51 · 2023: $85.75 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $555.05 | 2025 | |
| Pfizer INC. | $142.75 | 2025 | |
| Emd Serono, INC. | $139.47 | 2020-2025 | |
| Genzyme Corporation | $127.85 | 2023-2025 | |
| Lilly USA, LLC | $105.83 | 2025 | Amyvid, Kisunla, Zepbound |
| Argenx US, INC. | $94.55 | 2025 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $94.02 | 2025 | |
| Acadia Pharmaceuticals INC | $89.34 | 2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $65.20 | 2025 | |
| Ucb, INC. | $63.99 | 2025 | Nayzilam, Briviact |
| Inspire Medical Systems, INC. | $56.66 | 2025 | Inspire |
| Genentech USA, INC. | $54.43 | 2025 | Ocrevus Zunovo |
| Tg Therapeutics, INC. | $52.53 | 2025 | |
| Aucta Pharmaceuticals, INC. | $49.96 | 2025 | Motpoly Xr |
| Tanabe Pharma America, INC. | $46.26 | 2025 | Radicava |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $40.42 | 2025 | Crexont |
| Neurocrine Biosciences, INC. | $38.48 | 2025 | |
| Neurelis, INC. | $36.76 | 2025 | Valtoco |
| Eisai INC. | $35.68 | 2025 | |
| Axsome Therapeutics, INC. | $33.82 | 2025 | Symbravo, Sunosi |
| Alexion Pharmaceuticals, INC. | $30.91 | 2025 | Ultomiris |
| Sk Life Science, INC. | $27.23 | 2025 | |
| Lundbeck LLC | $25.81 | 2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $24.89 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $24.00 | 2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $23.35 | 2025 | |
| Abbott Laboratories | $23.15 | 2025 | Infinity |
| Ani Pharmaceuticals, INC. | $20.76 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $19.62 | 2025 | Acthar |
| Merz Pharmaceuticals, LLC | $16.61 | 2025 | Xeomin |
| Philips North America LLC | $15.47 | 2025 | Patient Interface Software |
| Csl Behring | $15.24 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Grossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.